Low levels of myostatin may impair muscular atrophy and dystrophy treatments

In a paper published in Nature Communications, researchers from University College London and colleagues showed that the myostatin (MSTN; GDF8) pathway is downregulated in muscle wasting or atrophying diseases, providing a potential explanation for why

Read the full 355 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE